Overview

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Abbott
Treatments:
Adalimumab
Methotrexate
Criteria
Inclusion Criteria:

- Subject was age 18 or older and in good health (Investigator discretion) with a recent
stable medical history who has had a diagnosis of psoriasis for at least 12 months and
stable moderate to severe chronic plaque psoriasis

- Subject is a candidate for systemic therapy or phototherapy and has active psoriasis
despite treatment with topical agents.

- Subject was able and willing to self-administer sc injections or had available
qualified person(s) to administer sc injections.

- Male subjects must hve been vasectomized or practicing birth control.

Exclusion Criteria:

- Previous systemic anti-TNF therapy.

- Prior use of MTX.

- Known hypersensitivity to the constituents of adalimumab.

- Systemic therapy for psoriasis for at least 4 weeks prior to Baseline; except for
biologic therapies, which must be discontinued at least 12 weeks prior to enrollment.

- Topical psoriasis therapy for at least 2 weeks prior to Baseline, except for
non-corticosteroid shampoos, bland (no alpha or beta hydroxy) emollients and low
potency topical corticosteroids on the palms, soles, face, inframammary area, and
groin only.

- Use of tanning beds, excessive sun exposure, or phototherapy (UVB, UVA), for at least
2 weeks prior to Baseline.

- Use of PUVA for at least 4 weeks prior to Baseline.

- Use of oral or injectable corticosteroids during the study.

- Subject considered by the investigator, for any reason, to be an unsuitable candidate
for the study.

- Female subject who is pregnant or breast feeding or considering becoming pregnant.